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Abstract Chronic myelogenous leukemia (CML) is associated
with the presence of the Philadelphia chromosome, which is
generated by the reciprocal translocation of chromosomes 9 and
22. In the case of L6 (b2a2) mRNA, it is difficult to cleave the
abnormal mRNA specifically because the mRNA includes no
sequences that can be cleaved efficiently by conventional
hammerhead ribozymes near the BCR-ABL junction. We
recently succeeded in designing a novel maxizyme, which
specifically cleaves BCR-ABL fusion mRNA, as a result of the
formation of a dimeric structure. As an extension of our
molecular engineering of maxizymes, as well as to improve their
potential utility, we examined whether an analogous conforma-
tional change could be induced within a single molecule when two
maxizymes were connected via a linker sequence. An active
conformation was achieved by binding of the construct to the
BCR-ABL junction in trans, with part of the linker sequence then
acting as an antisense modulator in cis (within the complex) to
adjust the overall structure. Results of studies in vitro in the
presence of cetyltrimethylammonium bromide (CTAB) (but not
in its absence) suggested that a certain kind of connected
maxizyme (cMzB) might be able to undergo a desired
conformational change and, indeed, studies in vivo confirmed
this prediction. Therefore, we successfully created a fully
functional, connected maxizyme and, moreover, we found that
the activity and specificity of catalytic RNAs in vivo might be
better estimated if their reactions are monitored in vitro in the
presence of CTAB.
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1. Introduction
The hammerhead ribozyme, which is the smallest natural
catalytic RNA identi¢ed to date, was ¢rst detected in certain
small satellite and viroid RNAs [1^5]. Because the catalytic
motif is so compact, hammerhead ribozymes have been engi-
neered to act in trans to cleave other RNA molecules [6,7].
The trans-acting hammerhead ribozyme consists of an anti-
sense section (stems I and III) and a catalytic domain with a
£anking stem-loop II section (Fig. 1A) [8]. When stems I and
III are designed as antisense sequences complementary to tar-
get mRNAs, the hammerhead can be utilized as a potential
therapeutic agent or tool for the regulation of expression of a
speci¢c gene [8^17].
Chronic myelogenous leukemia (CML), which is a clonal
myeloproliferative disorder of hematopoietic stem cells, ac-
counts for about 15^20% of all leukemias [18]. The Philadel-
phia chromosome (Ph1), which is caused by reciprocal trans-
location of chromosomes 9 and 22, is characteristically
detectable in more than 95% of patients with CML. The
breakpoints on chromosome 22 are clustered within a 6-kb
region known as the breakpoints cluster region (bcr), while
the breakpoints on chromosome 9 are spread over a 90-kb
region upstream of exon 2 of c-abl [19^24]. The BCR-ABL
fusion gene, after splicing, generates two di¡erent BCR-ABL
fusion mRNAs, namely K28 b3a2 mRNA and L6 (b2a2)
mRNA (Fig. 2). These mRNAs are translated into
p210BCRÿABL protein, which has elevated tyrosine kinase ac-
tivity and causes the malignant cell phenotype [25].
If a ribozyme is to disrupt chimeric BCR-ABL mRNA, it
must target the junction sequence exclusively. Otherwise, nor-
mal mRNAs that share part of the chimeric RNA sequence
will also be cleaved by the ribozyme, with resultant damage to
host cells. In the case of the K28 BCR-ABL chimeric b3a2
RNA sequence (Fig. 2), a potential site of cleavage by a ri-
bozyme, a GUU triplet, is located three nucleotides upstream
of the chimeric junction. Thus, a conventionally designed
hammerhead ribozyme might be expected to cleave speci¢cally
the abnormal mRNA generated from K28 translocations. In-
deed, several examples of such cleavage have been reported
[26^33]. By contrast, in the case of the b2a2 sequence, which
results from L6 translocations, as well as in the case of some
K28 translocations, there are no triplet sequences that are
potentially cleavable by hammerhead ribozymes within two
or three nucleotides of the junction in question. GUC triplets
are generally the triplets that are most susceptible to cleavage
by a hammerhead ribozyme [34^38], and one such triplet is
located 45 nucleotides from the junction (Fig. 2). If this GUC
triplet were targeted by a ribozyme, the normal ABL mRNA,
which shares part of the sequence of the abnormal BCR-ABL
mRNA, would also be cleaved by the ribozyme, with resultant
damage to the host cells [39]. In designing ribozymes that
might cleave b2a2 mRNA, we must be careful to avoid cleav-
age of normal ABL mRNA.
We demonstrated previously that shortened forms of (stem
II-deleted) hammerhead ribozymes, with low intrinsic activity,
form very active dimers with a common stem II (Fig. 1B) [40].
In order to distinguish monomeric forms of conventional min-
izymes that have low activity from our novel dimers with
high-level activity, the latter very active short ribozymes,
which are capable of forming dimers, are designated ‘maxi-
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zymes’, abbreviated as ‘Mz’ [39,41]. The dimers can be homo-
dimeric (with two identical binding sequences) or heterodi-
meric (with two di¡erent binding sequences; Fig. 1B). A het-
erodimer has two di¡erent substrate binding regions and two
catalytic domains [41,42]. Because of the two independent
catalytic cores, a heterodimer can cleave a single substrate
at two independent sites simultaneously (in contrast to homo-
dimeric maxizymes that cleave at one site only) [41]. More-
over, one of the catalytic domains of the heterodimer can be
converted to a sensor arm that can allosterically regulate the
activity of the maxizyme [39]. Thus, one of our maxizymes
was designed to adopt an active conformation only in the
presence of an abnormal BCR-ABL junction, while the con-
formation remains inactive in the presence of the normal ABL
mRNA, as well as in the absence of the abnormal BCR-ABL
junction (see Fig. 1 of Kuwabara et al. [39]). Studies in vitro
and in cultured cells demonstrated that such conformational
changes did indeed occur and depended on the presence or
absence of the abnormal BCR-ABL mRNA [39]. This phe-
nomenon resembles the changes in conformation of allosteric
proteinaceous enzymes that occur in response to their e¡ector
molecules, and ours was the ¢rst demonstration of an arti¢-
Fig. 1. Secondary structures of a hammerhead ribozyme and of maxizymes. A: The secondary structure of the parental hammerhead ribozyme
consists of an antisense section (stems I and III) and a catalytic domain with a £anking stem/loop II section (left). The secondary structure of
a monomeric minizyme, namely, a conventional hammerhead ribozyme with a deleted stem/loop II region, is shown on the right. B: Secondary
structure of a maxizyme that is capable of forming a homodimer (top) and a heterodimer (bottom). The homodimer has two identical binding
sites, while the heterodimer can generate two di¡erent binding sites, one of which is complementary to the sequence of one substrate and one
of which is complementary to a second substrate. Maxizyme left (MzL) and maxizyme right (MzR) form the heterodimeric maxizyme (bottom).
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cially created ribozyme whose catalytic activity is under per-
fect allosteric control, not only in vitro but also in cultured
cells.
In the case of heterodimeric maxizymes in general, dimeri-
zation can potentially generate a mixture of inactive
(MzRWMzR) dimers (consisting of two identical forms of max-
izyme right), inactive (MzLWMzL) dimers (consisting of two
identical forms of maxizyme left), and the desired active
(MzRWMzL) dimers (consisting of maxizyme right and maxi-
zyme left). Such a mixed population of dimers is one of the
reasons for the low activity of some maxizymes, at least in
vitro [43]. In order to avoid formation of such inactive homo-
dimers, as well as to enhance the potential utility of maxi-
zymes, we postulated that it might be possible to connect
two types of maxizyme (namely, MzR and MzL), transcribed
under the control of a single promoter, without sacri¢cing the
activity and speci¢city of the dimeric maxizyme.
We demonstrate in this paper that the catalytic activity of a
speci¢cally designed connected-type maxizyme (cMz) can be
controlled allosterically in the presence of the junction in
BCR-ABL chimeric L6 (b2a2) mRNA. Moreover, although
activities of catalytic RNAs in vitro do not necessarily re£ect
their activities in vivo, we found that the activity and speci¢c-
ity of connected maxizymes in vivo can be better estimated by
monitoring their kinetic behaviors in the presence of cetyltri-
methylammonium bromide (CTAB) in vitro.
2. Materials and methods
2.1. Transcription of connected maxizymes (cMz)
DNA templates for connected maxizymes (cMz) were synthesized
chemically by a DNA/RNA synthesizer (model 394; Perkin Elmer,
Applied Biosystems (ABI), Foster City, CA). The templates for T7
transcription had the following sequences: cMz1, 5P-CAC TCA CTG
ATG AGA GTT ATT GAT GGT CAG GTT ATA ATA AGA AAG
AAA AGA AGG GCT TCT TTC ATC GAA ACC CTG AGG-3P ;
cMz2, 5P-CAC TCA CTG ATG AGA GTT ATT GAT GGT CAG
AAA AAA AAA AAA AAA GAA GGG CTT TCA TCG AAA
CCC TGA GG-3P ; cMz3, 5P-GAA GGG CTT CTT TCA TCG
AAA CCC TGA GGA AAA AAA AAA AAA AAC ACT CAC
TGA GAG TTA TTG ATG GTC AG-3P ; cMz4, 5P-GAA GGG
CTT CTT TCA TCG AAA CCC TGA GGA AAT AAT AAA
GAA AGA AAA CAC TCA CTG ATG AGA GTT ATT GAT
GGT CAG-3P ; cMzA, 5P-GAA GGG CTT CTT TCA TCG AAA
CCC TGA GGA ATA GAT CTA AAA GAA TGC TGT GAA
AGA AAG CGA ATA CAC TCA CTG ATG AGA GTT ATT
GAT GGT CAG-3P ; and cMzB, 5P-GAA GGG CTT CTT TCA
TCG AAA CCC TGA GGA AAA CTC AAA GTC AAA AAA
AAC ACT CAC TAA TGA GAG TTA TTG ATG GTC AG-3P.
Primers were also synthesized for each template, and sense strands
included the T7 promoter. Products of the polymerase chain reaction
(PCR) were puri¢ed on an agarose gel. T7 transcription in vitro and
gel-electrophoretic puri¢cation of each cMz were performed as de-
scribed elsewhere [37].
2.2. Synthesis of target substrates
Short substrates for kinetics (S16, BCR-ABL pseudo-sub) were
chemically synthesized on a DNA/RNA synthesizer. S16 which con-
tained GUC triplet located 45 nucleotides 3P of the BCR-ABL junc-
tion had the following sequence: 5P-CCU CAG GGU CUG AGU G-
3P. BCR-ABL pseudo-sub which contained BCR-ABL mRNA se-
quence around the BCR-ABL junction had the following sequence:
5P-CUG ACC AUC AAU AAG GAA GAA GCC CUU C-3P.
DNA templates for L6 BCR-ABL substrate RNA and the normal
ABL substrate RNAs were synthesized chemically. The DNA oligo-
deoxynucleotide template for L6 BCR-ABL substrate RNA consisted
of the sequence from 63 nucleotides 5P of the BCR-ABL junction to 58
nucleotides 3P of the BCR-ABL junction. The region of the DNA
oligodeoxynucleotide template for the normal ABL substrate RNA
extended from position 192 to position 283 of normal ABL cDNA.
Primers were also synthesized for each template, and each sense
strand contained the T7 promoter. The products of PCR were gel-
puri¢ed. T7 transcription in vitro and gel-electrophoretic puri¢cation
of the ABL and BCR-ABL mRNA substrates were performed as
described elsewhere [37].
2.3. Measurements of kinetic parameters
Measurements of kinetic parameters of reactions catalyzed by
cMz1^4 were made with 5P-32P-labeled short substrates (S16). Reac-
tion rates were measured, in 25 mM MgCl2, 50 mM Tris-HCl (pH
8.0) and 10 mM NaCl under single-turnover conditions at 37‡C with
28-mer BCR-ABL (1 WM) as the e¡ector molecule. Reactions were
initiated by addition of appropriate amounts of MgCl2 after pre-in-
cubation of a reaction mixture that contained all components except
MgCl2 for several minutes at 37‡C. Reactions were stopped by re-
moval of aliquots from the reaction mixture at appropriate intervals
and mixing them with an equivalent volume of a solution that con-
tained 100 mM EDTA, 9 M urea, 0.1% xylene cyanol, and 0.1%
bromophenol blue. The substrate and the products of the reaction
were separated by electrophoresis on a 5% polyacrylamide/7 M urea
denaturing gel and were detected by autoradiography. The extent of
cleavage was determined by quantitation of radioactivity in the bands
of substrate and products with a Bio-Image Analyzer (BAS2000; Fuji
Film, Tokyo).
2.4. Speci¢city and kinetic analysis of the cleavage of BCR-ABL
chimeric L6 (b2a2) mRNA by cMzA and cMzB in the presence of
CTAB
For the examination of speci¢city, when reactions were catalyzed by
cMzA and cMzB, 5P-32P-labeled long substrates (L6 BCR-ABL sub-
strate RNA and normal ABL substrate RNA) were used. The sub-
strates were 5P-labeled with [32P]ATP by T4 polynucleotide kinase
Fig. 2. Translocations and possible sites of cleavage by conventional
ribozymes within normal ABL mRNA and within abnormal BCR-
ABL fusion mRNAs. Schematic representations of the two types of
chromosomal translocation (K28-type and L6-type, upper panel)
that are associated with CML and the corresponding fusion
mRNAs are shown (lower section). Boxes in gray represent BCR
exons and boxes in black represent ABL exon 2. Dotted lines con-
necting BCR and ABL exons indicate alternative splicing pathways.
Ph1, Philadelphia chromosome.
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(Takara Shuzo, Kyoto). In order to characterize in further detail the
properties of cMz4, cMzA and cMzB, we determined the kinetic pa-
rameters of cleavage using long substrates (see the table at the bottom
of Fig. 6). Reactions were performed, in 25 mM MgCl2, 50 mM Tris-
HCl (pH 8.0) and 10 mM NaCl under single-turnover conditions at
37‡C, in the presence or absence of 50 WM CTAB (Sigma, St. Louis,
MO). Reactions were initiated by the addition of MgCl2 to a bu¡ered
solution that contained each enzyme with the substrate, and each
resultant mixture was then incubated at 37‡C. Reactions were stopped
by removal of aliquots from the reaction mixture at appropriate in-
tervals and mixing them with an equal volume of a solution that
contained 100 mM EDTA, 9 M urea, 0.1% xylene cyanol, and 0.1%
bromophenol blue. Finally, reaction mixtures were subjected to elec-
trophoresis on 5% polyacrylamide/7 M urea gel. Rate constants are
averages from three sets of experiments.
2.5. Construction of plasmids for the expression of connected
maxizymes
Chemically synthesized oligonucleotides encoding each ribozyme
(cMzA, cMzB) and the polymerase (pol) III termination sequence
[44] were converted to double-stranded sequences by PCR. After di-
gestion with Csp45I and SalI, each appropriate fragment was cloned
downstream of the promoter of the gene for tRNAVal pV (in which
the chemically synthesized promoter of a human gene for tRNAVal
had been ligated between the EcoRI and SalI sites of the pMX puro
vector) [45]. The sequences of the constructs were con¢rmed by direct
sequencing.
2.6. Assays of reporter activity after transient transfection
The vectors shown in Fig. 7A were used to transfect HeLa cells in
combination with Lipofectin Reagent (Gibco-BRL, Rockville, MD).
Luciferase activity was measured with a Pica Gene kit (Toyo-inki,
Tokyo) as described elsewhere [46]. In order to normalize the e⁄-
ciency of transfection by reference to L-galactosidase activity, cells
were co-transfected with the pSV-L-galactosidase control vector
(Promega, Madison, WI) and then the chemiluminescent signal due
to L-galactosidase activity was quantitated with a luminescent L-gal-
actosidase genetic reporter system (Clontech, Palo Alto, CA) as de-
scribed previously [46]. The results shown are the averages of results
from more than three sets of experiments.
Table 1
Kinetic parameters for reactions catalyzed by the ¢rst generation of
connected maxizymesa





aKinetic measurements were made in 50 mM Tris-HCl (pH 8.0) and
25 mM MgCl2, under enzyme-saturating conditions at 37‡C with
the 28-mer BCR-ABL junction-containing RNA (1 WM) as the e¡ec-
tor molecule. Rate constants are averages from three sets of experi-
ments.
Fig. 3. Secondary structures of a connected maxizyme (cMz) and its target. Connected maxizymes are generated in two ways, as indicated by
type I and type II. CMz1 and cMz2 belong to type I construct. CMz3 and cMz4 belong to type II construct.
FEBS 22804 4-11-99
M. Hamada et al./FEBS Letters 461 (1999) 77^8580
3. Results and discussion
3.1. Design of connected maxizymes (cMz1^cMz4) and their
speci¢city with respect to the cleavage of BCR-ABL
chimeric L6 (b2a2) mRNA
For the potential future application of dimeric maxizymes
as a potential treatment for CML, we attempted to design
new connected maxizyme motifs that would speci¢cally cleave
BCR-ABL chimeric L6 (b2a2) mRNA. First, we designed and
synthesized, by T7 transcription from the corresponding DNA
templates, four connected maxizymes, cMz1^4 (Fig. 3). Max-
izymes can be connected in at least two ways, as indicated by
type I and type II in Fig. 3. Two constructs, cMz1 and cMz2,
belong to the type I construct in that the sensor arms of MzR
and MzL, which recognize the abnormal BCR-ABL junction,
were connected by a linker sequence between the 5P-end of
MzR and the 3P-end of MzL (dotted line in the general struc-
ture of maxizyme; right panel). In the type II constructs,
cMz3 and cMz4, MzR and MzL were connected at the sub-
strate recognition arms, which correspond to stems I and III
of the parental hammerhead ribozyme (Fig. 1A, left), by a
linker that connected the 5P-end of MzL and the 3P-end of
MzR.
In order to examine the activity of the maxizymes in vitro,
we at ¢rst used a short 16 nucleotides BCR-ABL substrate
that corresponded to the target (cleavage) site (the substrate
used, S16, is indicated in Fig. 3). Kinetic measurements of the
kcat and Kd(app) values listed in Table 1 were made in 25 mM
Fig. 4. Schematic representation of allosteric control with two types of activation by a novel connected maxizyme. A conformational change
should be induced within a single molecule when maxizymes are connected via a linker sequence. The active conformation is achieved by bind-
ing to the BCR-ABL junction in trans. Then a part of the linker sequence acts as an antisense modulator in cis to adjust the overall structure.
The alternative sequence of events is also possible.
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MgCl2 and 50 mM Tris-HCl (pH 8.0), under enzyme-saturat-
ing (single-turnover) conditions at 37‡C with the 28-mer BCR-
ABL junction-containing RNA (1 WM) as the e¡ector mole-
cule, and the cleavage products were analyzed on a denaturing
polyacrylamide gel as described in Section 2. Comparison of
kinetic parameters revealed that type I connected maxizymes
were as active as their parental dimeric maxizyme in vitro, and
they were more active than type II maxizymes. However, un-
fortunately, those type I maxizymes (cMz1 and cMz2) with
higher activity cleaved the substrate (S16) not only in the
presence of the 28-mer e¡ector molecule (BCR-ABL junction)
but cleavage also occurred at a similar rate in the absence of
the e¡ector molecule, whereas type II maxizymes (cMz3 and
cMz4) with lower activity retained some speci¢city (data not
shown). Therefore, all (for cMz1 and cMz2) or a signi¢cant
part (for cMz3 and cMz4) of the speci¢city was lost by simply
connecting two independent maxizyme units (MzR and MzL).
Since speci¢city is one of the most important factors in the
design of maxizymes that are to disrupt a chimeric mRNA
and since cleavage of normal mRNA must be avoided to
avoid damage to host cells, we decided that the molecular
design of connected maxizymes would have to be based on
the type II construct.
3.2. Second generation of connected maxizymes (cMzA and
cMzB) and re-examination of their speci¢city with respect
to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA
in the presence and in the absence of CTAB
Since the ¢rst generation of simply connected maxizymes
(cMz) failed to exhibit reasonable speci¢city in vitro, we de-
cided to introduce additional features that would favor the
formation of a correctly folded complex. To improve the
type II motif, we attempted to increase the speci¢city with
respect to the cleavage of BCR-ABL chimeric L6 (b2a2)
mRNA by introducing an antisense modulator within the
linker sequence. We hoped that the size of the population of
correctly folded complexes would increase as a result of the
formation of basepairs with part of the target mRNA, as
shown schematically in the lower part in Fig. 4. The inserted
antisense modulator sequences in the two connected maxi-
zymes (cMzA and cMzB) are indicated in Fig. 5.
In order to examine the activity and speci¢city of T7 tran-
scribed cMzA and cMzB in vitro, we prepared by T7 tran-
scription the normal ABL substrate [47] and the chimeric
BCR-ABL substrate (Fig. 5C), respectively, of 92 and 121
nucleotides, that are expected to be better substrates than
shorter ones in the prediction of the connected maxizymes’
Fig. 5. Secondary structures of the connected maxizyme (cMz) and the target. A, B: Secondary structures of two connected maxizymes, cMzA
and cMzB, with antisense modulator sequences. To improve the type II motif, an antisense modulator was introduced within the linker se-
quence so that the size of the population of correctly folded complexes would be increased by formation of basepairs with part of the target
mRNA, with resultant correct basepairing of the maxizyme with the cleavage site. C: The secondary structure of BCR-ABL mRNA around
the b2a2 junction. The BCR exon 2 sequence is depicted by lower-case letters and that of the ABL exon 2 sequence is depicted by capital let-
ters. Complementary sequences to each antisense modulator of cMzA and cMzB are also shown. Cleavage site by connected maxizymes is indi-
cated with scissors.
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speci¢city in vivo. Moreover, the cationic detergent CTAB,
which is known to enhance strand displacement of nucleic
acids, was also used in the prediction in vitro of the connected
maxizymes’ speci¢city in vivo, since our previous study dem-
onstrated that the activity of ribozymes in vivo can be better
estimated by monitoring ribozyme kinetics in the presence of
CTAB in vitro [43]. We performed kinetic analyses by running
reactions in mixtures that contained 50 mM Tris-HCl (pH
8.0), 10 mM NaCl, and 25 mM MgCl2, at 37‡C under sin-
gle-turnover conditions, using a ¢xed concentration of the
connected maxizyme, cMzA or cMzB (50 nM), and with or
without a ¢xed concentration of CTAB (50 WM) that was
slightly above its critical micelle concentration (CMC).
To our surprise, when the longer substrates were used,
cMz4, which showed some speci¢city with the short 16-mer
substrate, cleaved both the abnormal BCR-ABL substrate
(lane 13 in Fig. 6) as well as the normal ABL substrate
(lane 6) with a similar e⁄ciency in the absence of CTAB
(see rate constants at the bottom of Fig. 6). Upon addition
of CTAB, cMz4 gained limited speci¢city (see lanes 7 and 14,
and the table in Fig. 6). In the case of cMzA, CTAB accel-
erated the cleavage of not only the abnormal BCR-ABL sub-
strate (lanes 9 and 10) but also, and even to a greater extent,
the normal ABL substrate (compare lanes 2 and 3, and see the
table for rate constants).
Fortunately, cMzB, which did not show speci¢city in the
absence of CTAB (lanes 4 and 11), started to demonstrate
speci¢city upon addition of CTAB (lanes 5 and 12, and rate
constants in Fig. 6). In designing the second generation of
connected maxizymes, cMzA and cMzB, we took care to en-
sure that the linker region would not form intramolecular
basepairs within cMz. However, it was impossible to predict,
at least by computer folding analysis, which cMz would have
greater speci¢city.
Many so-called facilitators have recently been identi¢ed
that signi¢cantly increase the rates of formation of RNA du-
plexes and of ribozyme-catalyzed reactions [48^59]. These fa-
cilitators include nuclear proteins, the HIV-1 nucleocapsid
protein, and cationic detergents. It seems possible, therefore,
that the capacity of ribozymes for the rapid and speci¢c cleav-
age of RNAs in vivo might be enhanced by such facilitators if
ribozymes or substrates in an inactive conformation could be
converted to active forms in vivo. Our previous study demon-
strated that various kinds of facilitator in vivo that function
similarly to CTAB might enhance the activity of dimeric max-
izymes and that CTAB appears to be useful in predicting
activities of ribozymes in vivo [43]. As will be shown below,
the present study demonstrates that CTAB appears to be use-
ful in predicting not only the relative activity of ribozymes but
also the speci¢city of the maxizymes, namely, as predicted in
this section in the presence of CTAB, only cMzB demon-
strates high speci¢city in cultured cells.
3.3. Connected maxizymes under the control of a human
tRNAVal promoter and their activities in vivo
For application of connected maxizymes to gene therapy,
the e¡ective delivery into cells and the high-level expression of
connected maxizymes are obviously critically important. In
our laboratory, we have exploited an endogenous delivery
system that is quite e⁄cient [60]. We use the promoter of a
human gene for tRNAVal [13,15,61^63] that is recognized by
RNA pol III [36,44]. While pol II promoters might allow
tissue-speci¢c or regulatable expression, we anticipated that
pol III transcripts might be expressed at signi¢cantly higher
levels. It would clearly be advantageous to use a strong pro-
moter for transcription of ribozymes and maxizymes because
high-level expression would be more likely to ensure signi¢-
cant suppression of the expression of a speci¢c gene [60]. The
tRNAVal-expression system resulted in high-level activity of
ribozymes and maxizymes in cultured cells [13,15,39,41,60].
Therefore, we embedded cMzA and cMzB similarly in the
3P portion of the human gene for tRNAVal (Fig. 7). To exam-
ine the activity and the speci¢city of tRNAVal-driven maxi-
zymes, we used a reporter construct in a transient assay (Fig.
7A). We co-transfected HeLa cells with various expression
plasmids that encoded appropriate maxizymes under the con-
trol of the human tRNAVal-promoter, as well as a target gene-
expressing plasmid that encoded a chimeric target BCR-ABL
sequence (or ABL alone) and a gene for luciferase, pB2A2-luc
(or pABL-luc), as described in detail in [39]. The luciferase
activity recorded when we used the target gene-expressing
plasmid and of the tRNAVal-portion-expressing plasmid
(pV) was taken as 100% (Fig. 7B). In accord with the results
of kinetic measurements in the presence of CTAB, one of the
Fig. 6. The speci¢city of cMz with respect to the cleavage of BCR-
ABL substrate in the presence and in the absence of CTAB. Kinetic
parameters for the cleavage of BCR-ABL mRNA (121-mer sub-
strate) and ABL mRNA (92-mer), in the presence and in the ab-
sence of CTAB, are also shown in the table at the bottom. All reac-
tions were measured in 50 mM Tris-HCl (pH 8.0), 25 mM MgCl2
and 10 mM NaCl in the presence or absence of 50 WM CTAB
under enzymes saturating (single-turnover) conditions at 37‡C. Rate
constants are averages from three sets of experiments.
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connected maxizymes (cMzB) was signi¢cantly more speci¢c,
in cleaving the abnormal BCR-ABL-luciferase gene without
damaging the normal ABL-luciferase gene, than the other
connected maxizymes (cMzA).
In conclusion, for the future treatment of CML by ribo-
zymes, we designed and analyzed new RNA motifs, putting
some emphasis on the speci¢city with respect to the cleavage
of BCR-ABL chimeric L6 (b2a2) mRNA. We con¢rmed that
cMzB retained the speci¢city with respect to the cleavage of
BCR-ABL chimeric L6 (b2a2) mRNA. In the case of cMzA,
the antisense modulator complementary to part of the BCR
was included in the linker sequence. On the other hand, in the
case of cMzB, the antisense modulator complementary to part
of the ABL was included in the linker sequence. Although it
was not possible to predict their activity and speci¢city from
their computer-predicted structures nor from their kinetic be-
haviors in the absence of CTAB, it is signi¢cant that not only
their activity but also their speci¢city in vivo could be esti-
mated from their kinetics in vitro when reactions were carried
out in the presence of CTAB. These ¢ndings suggest that,
even though the activities and speci¢cities in vitro of ribo-
zymes in general do not necessarily re£ect their activities in
vivo, it might be possible to predict their activities and spe-
ci¢cities in vivo by monitoring their activities and speci¢cities
in vitro in the presence of CTAB.
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